Healthy Volunteer.
Conditions
Interventions
Intervention 1: Intervention group: They will take Loratadine oral tablets with a dose of 10 mg for 21 days, and after that, they will receive the same placebo for 21 days. Intervention 2: Control gro
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Healthy volunteer Written consent to enter the study
Exclusion criteria
Exclusion criteria: History of constant use of antihistamines during last 3 month Pregnancy Breastfeeding History of any underlying chronic disorder History of allergic disorders History of atopy History of rheumatological disorders Smoking History of malignancies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the number of T regulatory cells in venous blood. Timepoint: Before, after 21 days, after 42 days. Method of measurement: Flow cytometry technique. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of CD8+ effector T Cells. Timepoint: Before, after 21 days, after 42 days. Method of measurement: Flow cytometry technique. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHadi Esmaily
Shahid Beheshti University of Medical Sciences
Outcome results
None listed